



**CPAL**

Central Pennsylvania Alliance Laboratory

**Technical Bulletin**

**No. 96**

**November 8, 2011**

**KRAS and BRAF Mutation Assay  
Additional Information Required  
with Submitted Samples**

**Contact:**

Dr. Jeffrey Wisotzkey, 717-851-1422  
*Technical Director, CPAL*

Jill Johns, MT(ASCP), SH, QCYM, 717-851-4320  
*Operations Manager, CPAL*

**Effective Date:** 11/8/2011

**Summary:** Effective immediately an estimation of the neoplastic cell content of the selected “tumor” area **MUST** be indicated with specimens submitted for KRAS and/or BRAF mutational analysis. It is acceptable to indicate simply  $\geq 50\%$  neoplastic cell content or  $< 50\%$  neoplastic cell content. More specific estimates are acceptable.

Specimens in which no desired sampling area (tumor) and estimated neoplastic cell content is indicated will be returned to the client so that the proper region of interest and information can be indicated and resubmitted to CPAL.

Specimens should be transported and stored at room temperature.

Specific questions or concerns may be addressed to Dr. Wisotzkey

Issued on: November 8, 2011

For questions about this and other information, call Central Pennsylvania Alliance Laboratory at 1-888-480-1422.